Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-MSC intradiscal injection for degenerative disc disease
2019-002749-40Phase 2Active
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Jan 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of autologous bone-marrow mesenchymal stem cells in degenerative disc disease (DDD) (2 arms), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Responder efficacy at 24 months by pain and disability. Started Jan 2021; status: active.
02
Drugs
autologous bone-marrow mesenchymal stem cells
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on 2019-002749-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002749-40.